ArticlePharmaceutical research2022
Inhaled Indomethacin-Loaded Liposomes as Potential Therapeutics against Non-Small Cell Lung Cancer (NSCLC).
Article in Pharmaceutical research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- A novel therapeutic outlook: Classification, applications and challenges of inhalable micron/nanoparticle drug delivery systems in lung cancer (Review).International journal of oncology · 2024Pooled it
- The Application of Machine Learning in the Development of Co-Amorphous Dry Powder Inhalation.AAPS PharmSciTech · 2026Article
- Liposomal Amodiaquine for Localized Therapy of Non-Small Cell Lung Cancer (NSCLC).AAPS PharmSciTech · 2026Article
- Liposomal Amodiaquine for Localized Therapy of Non-Small Cell Lung Cancer (NSCLC).AAPS PharmSciTech · 2026Article
- 3D-Printed Microneedle Patch for the Treatment of Melanoma via Synergistic Chemotherapy and Photothermal Therapy.ACS applied bio materials · 2026Article
- Recent Advancements in Lung Cancer Metastasis Prevention Based on Nanostrategies.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Nanostructured Formulations for a Local Treatment of Cancer: A Mini Review About Challenges and Possibilities.Pharmaceutics · 2025Review
- Potential Effects of Indomethacin on Alleviating Osteoarthritis ProgressionJournal of musculoskeletal & neuronal interactions · 2024Article
- Lipid polymer hybrid nanoparticles against lung cancer and their application as inhalable formulation.Nanomedicine (London, England) · 2024Review
- Combination of Indomethacin with Nanostructured Lipid Carriers for Effective Anticancer Therapy.International journal of nanomedicine · 2024Article
- Nano-mediated strategy for targeting and treatment of non-small cell lung cancer (NSCLC).Naunyn-Schmiedeberg's archives of pharmacology · 2023Review
- Natural fulvic acids inhibit non-small-cell lung cancer through the COX-2/PGE2/EP4 axis: In silico and in vivo assessments.Heliyon · 2023Article
- Lipid-Based Inhalable Micro- and Nanocarriers of Active Agents for Treating Non-Small-Cell Lung Cancer.Pharmaceutics · 2023Review
- Discovery of Small Molecule COX-1 and Akt Inhibitors as Anti-NSCLC Agents Endowed with Anti-Inflammatory Action.International journal of molecular sciences · 2023Article
- Drug Repurposing in Non-Small Cell Lung Carcinoma: Old Solutions for New Problems.Current oncology (Toronto, Ont.) · 2023Review
- Nanotechnology boosts the efficiency of tumor diagnosis and therapy.Frontiers in bioengineering and biotechnology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Most lung cancer instances are non-small cell lung cancers (NSCLC). As stated by recent literature, cycloxygenase-2 (COX-2) is upregulated in lung adenocarcinomas. COX-2 relates to enhanced cell proliferation and reduced apoptosis; both of which are essential for an invasive tumor growth and metastasis. Thus, COX-2 inhibition forms an important checkpoint. Drug repurposing and nano drug delivery systems will enable the faster and more efficacious drug development. This study was designed to prepare, characterize, and establish superior effectiveness of indomethacin (IND), (a nonselective COX-2 inhibitor) as liposomes (IND-Lip). IND-Lip were made using thin film hydration method and physicochemical properties were characterized. Cell viability was performed on NSCLC cell lines (A549, H1299 and H460) Clonogenic, spheroidal, caspase and COX-2 assays were then carried out. IND-Lip were found to have optimum physicochemical properties. Based on IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.